Innogen Pharma jostles for a slice of the weight-loss market
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
PegBio aims to bulk up its finances to deliver weight-loss drugs
The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
CSPC Pharma weighs up diet drug for bigger bottom line
After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business Key Takeaways: CSPC…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Recent Articles
RELATED ARTICLES
-
PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
